A Study on the Immunization Schedule for the 13-Valent Pneumococcal Polysaccharide-Conjugate Vacc… (NCT07591181) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Study on the Immunization Schedule for the 13-Valent Pneumococcal Polysaccharide-Conjugate Vaccine in Healthy Infants
210 participantsStarted 2026-05-10
Plain-language summary
To compare the immunogenicity of the domestically produced PCV13 vaccine in healthy 2-month-old infants following administration via the 2+1 and 3+1 schedules, with the primary endpoint being the seroprevalence of specific IgG antibodies after completion of the vaccination series.To evaluate the safety of the 2+1 schedule in infants and young children (incidence of adverse events and serious adverse events).
Who can participate
Age range
60 Days – 89 Days
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. received any pneumococcal vaccine before enrollment or schedule to receive a non-study pneumococcal vaccine during the study
. A history of culture-confirmed invasive disease caused by Streptococcus pneumoniae
. Known allergy to vaccine components, including excipients, diphtheria toxoid, tetanus toxoid, etc.
. Acute illness at enrollment or axillary temperature \>37°C
. Immune deficiency, chronic illness, or use of immunosuppressive therapy
. Patients with thrombocytopenia, any coagulation disorder, or those receiving anticoagulant therapy
. Participation in another clinical trial within the past 30 days or during this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Seropositivity rate 30 days after the booster dose
Timeframe: 30 days after the booster dose
Trial details
NCT IDNCT07591181
SponsorBeijing Center for Disease Control and Prevention